Clinical trials: Etanercept
Rheumatoid Arthritis
Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)
Rheumatoid Arthritis (RA) is a systemic inflammatory autoimmune disorder that leads to inflammation and progressive joint damage affecting 2.5 million people in the United States.
- Trial name
- NCT00796705
- Testing
- Adalimumab, Etanercept
- Where
- 16 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatoid Arthritis
Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis
As stated by the European League Against Rheumatism (EULAR) and the Société Française de Rhumatologie (SFR), treatment of patients with rheumatoid arthritis (RA) should target sustained remission or at least low disease…
- Trial name
- CRI-RA (NCT04870203)
- Testing
- baricitinib treatment, anti-TNF therapy
- Where
- 36 sites in France, Monaco
- Volunteers
- 160 people
- Sponsor
- University Hospital, Bordeaux
Juvenile Rheumatoid Arthritis, Uveitis
TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis
This study will investigate the safety and effectiveness of the drug TNFR:Fc to treat uveitis (eye inflammation) in patients with juvenile rheumatoid arthritis.
- Trial name
- NCT00001862
- Testing
- Enbrel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Eye Institute (NEI)
Rheumatoid Arthritis
Comparative Effectiveness of Targeted Therapy in RA Patients
The objective of a multicenter prospective observational study is to compare effectiveness and safety of biologic disease-modifying antirheumatic drugs and small molecular inhibitors in patients with moderately to severely active…
- Trial name
- NCT04449224
- Testing
- Adalimuab, Etanercept, Tocilizumab, or Abatacept, Tofacitinib or Baricitinib
- Where
- South Korea
- Volunteers
- 506 people
- Sponsor
- Hanyang University
Plaque Psoriasis, Psoriasis
Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind, multicentral clinical trial to investigate the efficacy and safety of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection (Qiangke®) in the treatment of Moderate to Severe Plaque…
- Trial name
- NCT02701205
- Testing
- etanercept, etanercept (half dose)
- Where
- 4 sites in China
- Volunteers
- 216 people
- Sponsor
- Shanghai Celgen Bio-Pharmaceutical Co.,Ltd
Histiocytosis, Langerhans-Cell
Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL
The purpose of this study is to learn about the response of Langerhans cell histiocytosis (LCH) to Enbrel in patients who have failed to respond to standard therapies.
- Trial name
- NCT00048373
- Testing
- Etanercept
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Baylor College of Medicine
Diabetes Mellitus, Type 1
Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression
The primary purpose of this study is to demonstrate the safety of allogeneic islet transplantation in type 1 diabetic patients performed at the University of Illinois at Chicago (UIC).
- Trial name
- NCT00566813
- Testing
- Islet Cell Transplant, Islet Cell Transplant plus
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Illinois at Chicago
Psoriasis
Safety and Efficacy of Etanercept in Patients With Psoriasis
The purpose of this study is to evaluate safety and efficacy of etanercept in patients with psoriasis who had an unsatisfactory response to traditional DMARDs.
- Trial name
- NCT02258282
- Testing
- Etanercept, Control
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chengdu PLA General Hospital
Moderate to Severe Rheumatoid Arthritis
Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab
To evaluate the efficacy of etanercept in adults with moderate-to-severe rheumatoid arthritis (RA) who did not respond to or lost a satisfactory response to adalimumab when used as their first biologic agent.
- Trial name
- ROCkIES (NCT01927757)
- Testing
- Etanercept, Methotrexate
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 90 people
- Sponsor
- Amgen
Spondyloarthritis (SpA)
A Clinical Study to Evaluate the Efficacy of Biologics in SpA
Spondyloarthritis (SpA) is one of the potentially debilitating inflammatory diseases that affect the whole body, primarily burdening the sacroiliac joints and the spine. It mostly affects young and middle aged adults.
- Trial name
- NCT04399382
- Testing
- Biologics
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The University of Hong Kong-Shenzhen Hospital
Ankylosing Spondylitis
Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis
The primary objective of this study is to evaluate the efficacy of safety of etanercept dose reduction combined with sulfasalazine in ankylosing spondylitis (AS) patients who have achieved a significant clinical response.
- Trial name
- NCT02638896
- Testing
- etanercept (Half-Dose), etanercept (Full-Dose), Sulfasalazine
- Volunteers
- 100 people
- Sponsor
- Zhixiang Huang
Rheumatoid Arthritis
Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan
The special use-results surveillance is conducted in patients who have never been treated with Enbrel and in whom its long-term therapy may be instituted in the actual setting of use after marketing with the following objectives…
- Trial name
- NCT00503139
- Testing
- Enbrel (etanercept)
- Where
- Japan
- Volunteers
- 684 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid Arthritis
This is a descriptive, ambispective, and single-site study in Colombia, which is designed to evaluate the adherence, persistence, and clinical outcomes (defined as the patient's disease activity and functional status) of RA…
- Trial name
- NCT05891600
- Testing
- Etaneracept Smartclic
- Where
- Colombia
- Volunteers
- 60 people
- Sponsor
- Pfizer
Psoriasis
Etanercept Plus UVB-311nm Phototherapy in Psoriasis
Etanercept, a biological antipsoriatic drug with anti-tumor-necrosis factor (TNF) activity has been approved for the treatment of moderate to severe psoriasis.
- Trial name
- NCT00550030
- Testing
- UVB-311nm radiation, No treatment
- Where
- Austria
- Volunteers
- 6 people
- Sponsor
- Medical University of Graz
Rheumatoid Arthritis
Observational Trial With Enbrel
The diagnosis, evaluation and treatment of rheumatoid arthritis (RA) continue to undergo rapid change. Randomized controlled trials such as the TEMPO study have demonstrated the efficacy and safety of the combination of…
- Trial name
- NCT00488475
- Testing
- etanercept
- Where
- Germany
- Volunteers
- 4,945 people
- Sponsor
- Pfizer
Arthritis, Rheumatoid
A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
This is a randomized, double-blind, parallel group, multicenter clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of LBEC0101 compared to Enbrel in subjects with active Rheumatoid Arthritis…
- Trial name
- NCT02357069
- Testing
- Enbrel, LBEC0101
- Where
- 2 sites in Japan, South Korea
- Volunteers
- 372 people
- Sponsor
- LG Life Sciences
Hidradenitis Suppurativa
Etanercept in Hidradenitis Suppurativa
The rationale of the protocol is based on the reported beneficiary results of case-patients by the administration of other anti-TNF drug (infliximab) in separate cases on the grounds of a probable autoimmune predisposition of the…
- Trial name
- NCT00329823
- Testing
- Etanercept sc 50mg per week for 12 weeks
- Where
- Greece
- Volunteers
- 10 people
- Sponsor
- University of Athens
Rheumatoid Arthritis
Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)
1. To assess the baseline (i.e. RA therapy initiation) characteristics in a real-world setting across two moderate RA cohorts: a Test Group of patients newly exposed to etanercept (Enbrel) therapy and a Control Group of patients…
- Trial name
- NCT01557322
- Testing
- etanercept, methotrexate (MTX)
- Volunteers
- 1,754 people
- Sponsor
- Pfizer
de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes
Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes
This phase I/II trial studies how well giving azacitidine together with etanercept works in treating patients with myelodysplastic syndromes (MDS).
- Conditions
- de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
- Trial name
- NCT00118287
- Testing
- azacitidine, etanercept
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Fred Hutchinson Cancer Center
Rheumatoid Arthritis
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.
- Trial name
- RA-BRIDGE (NCT03915964)
- Testing
- Baricitinib, TNF Inhibitor
- Where
- 261 sites in United States, Australia and 22 more
- Volunteers
- 2,659 people
- Sponsor
- Eli Lilly and Company